The Cost Implications of Dabigatran in Patients with Myocardial Injury After Non-Cardiac Surgery
ConclusionDabigatran 110 mg twice daily was cost neutral for patients in the MANAGE trial. Our cost findings support the use of dabigatran 110 mg twice daily in patients with MINS.Trial RegistrationClinicalTrials.gov identifier number NCT01661101.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Canada Health | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Heart | Heart Attack | Hemorrhagic Stroke | Pradaxa | Stroke | Study | Thrombosis